ValenzaBio, Inc.

Industry

  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
See more in Biomedtracker

Latest on ValenzaBio, Inc.

Scrip

Acelyrin Belatedly Drops Izokibep In Its Lead Indications

 
• By Elizabeth Cairns

Acelyrin, Inc. has taken its time in coming to a sensible decision on izokibep. The company has terminated development of its IL-17A inhibitor izokibep in both hidradenitis suppurativa (HS) and psori

Scrip

Acelyrin Enters The Spotlight As NASDAQ Debut Dawns

 
• By Kevin Grogan

As observers eagerly await its listing on the US NASDAQ tomorrow (5 May), Acelyrin, Inc. has significantly upped the size of its initial public offering ahead of entry into the hot market of hidrade

Scrip

Deal Watch: AbbVie Leads J.P. Morgan Deal Rush, But BI, Genentech And Lilly Also Big Players

 
• By Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AbbVie Taps Anima’s mRNA Platform, Immu

Scrip

TED Talk: Viridian’s Early Data Indicate Strong Competitor To Horizon’s Tepezza

 
• By Joseph Haas

Horizon Therapeutics plc has had the thyroid eye disease (TED) market cornered since launching Tepezza (teprotumumab) in early 2020 and establishing a fast blockbuster drug, but Viridian Therapeutic